Olaparib in PALB2 Advanced Pancreatic Cancer

This study is testing olaparib — a targeted PARP inhibitor drug — in people with advanced pancreatic cancer who have a specific gene mutation called PALB2. Tumors with PALB2 mutations have trouble repairing DNA, which makes them potentially more vulnerable to olaparib. **You may be eligible if...** - You have been confirmed to have pancreatic adenocarcinoma (a common type of pancreatic cancer) through tissue or cell testing - Your cancer is advanced, unresectable (cannot be surgically removed), or has spread (metastatic) - You have a PALB2 gene mutation (in your blood or tumor) identified as harmful - You have at least one measurable tumor site **You may NOT be eligible if...** - You have a different type of pancreatic cancer (not adenocarcinoma) - You do not have a PALB2 mutation - Your cancer is resectable (can be surgically removed) Talk to your doctor to see if this trial is right for you.